1386861-46-6

Basic information

• Product Name: 2-Chloro-6-methyl-N-phenylbenzamide
• Synonyms: 2-Chloro-6-methyl-N-phenylbenzamide;EOS-60720
• CAS NO: 1386861-46-6
• Molecular Formula: C₁₄H₁₂ClNO
• Molecular Weight: 245.70418
• Mol File: 1386861-46-6.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 317.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.250±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• PKA: 12.85±0.70(Predicted)
• CAS DataBase Reference: 2-Chloro-6-methyl-N-phenylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-6-methyl-N-phenylbenzamide(1386861-46-6)
• EPA Substance Registry System: 2-Chloro-6-methyl-N-phenylbenzamide(1386861-46-6)

Safety Data

• Hazardous Substances Data: 1386861-46-6(Hazardous Substances Data)

Usage

General Description

2-chloro-6-methyl-N-phenylbenzamide is a chemical compound belonging to the benzamide family, with a molecular formula of C14H12ClNO. It is derived from benzene and contains a chlorine atom and a methyl group attached to the benzene ring. The compound also has an amide functional group, with a phenyl group attached to the amide nitrogen atom. 2-chloro-6-methyl-N-phenylbenzamide has relevance in the field of medicinal chemistry, with potential applications in drug synthesis and pharmaceutical research. Its specific chemical and physical properties make it suitable for various chemical reactions and interactions with biological systems.

Upstream product

• 118-91-2 ortho-chlorobenzoic acid 
• 21327-86-6 2-chloro-6-methylbenzoic acid 
• 89894-44-0 2-chloro-6-methylbenzoyl chloride 
• 62-53-3 aniline 

Downstream Products

• 1350643-72-9 (S)-3-(1-aminoethyl)-8-chloro-2-phenylisoquinoline-1(2H)-one 
• 1386861-47-7 tert-butyl (S)-(4-(3-chloro-2-(phenylcarbamoyl)phenyl)-3-oxobutane-2-yl)carbamate 
• 1420829-86-2 C₂₃H₁₇ClN₄OS 
• 1420829-90-8 C₂₆H₁₉N₇OS 
• 1420830-49-4 (S)-8-chloro-3-(1-(2-chloro-3-nitropyridine-4-ylamino)ethyl)-2-phenylisoquinolin-1(2H)-one 
• 1420830-50-7 C₂₂H₁₇ClN₄O₃S 
• 1420830-51-8 C₂₂H₁₉ClN₄OS 
• 1420830-03-0 C₂₇H₂₁N₇OS 
• 1420829-02-2 C₂₂H₁₆ClN₅OS 
• 1420829-04-4 C₂₆H₂₁N₇OS 
• 1420829-13-5 C₂₈H₁₉F₃N₆OS 
• 1420618-39-8 C₂₄H₁₈ClN₅O 
• 1420623-46-6 C₁₉H₁₄Cl₂N₄OS 
• 1420623-31-9 C₂₃H₁₈ClN₇O 

Relevant articles and documents

Alkyne derivative, preparation method and application thereof

The invention relates to an alkyne derivative and a preparation method thereof and application of the alkyne derivative in medicine, specifically to an alkyne derivative represented by general formula(I), a preparation method and a pharmaceutically accept

HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a heteroaryl derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting PI3 kinases, thereby being useful in preventing or treating PI3 kinase diseases such as: cancers, autoimmune diseases, and respiratory diseases.

Dihydropteridin-one derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and pharmaceutical composition for use in preventing or treating PI3 kinase related diseases

The present invention relates to dihydropteridin-one derivatives or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same as an effective component for preventing or treating PI3 kinase-related diseases. According to the present invention, the dihydropteridin-one derivatives have excellent selective inhibitory effects on PI3 kinase, and thus may be beneficially used in preventing or treating PI3 kinase-related diseases such as the following: cancers including blood cancer, ovarian cancer, cervical cancer, breast cancer, large intestine cancer, liver cancer, stomach cancer, pancreatic cancer, colon cancer, periotoneal cancer, skin cancer, bladder cancer, prostate cancer, lung cancer, osteosarcoma, fibrous tumor, and brain tumor; autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, type 1 diabetes, hyperthyroidism, myasthenia gravis, Crohnandprime;s disease, ankylosing spondylitis, psoriasis, pernicious anemia, and Sjogrenandprime;s syndrome; and respiratory diseases including chronic obstructive pulmonary disease (COPD), rhinitis, asthma, chronic bronchitis, chronic pulmonary inflammatory diseases, silicosis, pulmonary sarcoidosis, pleuritis, alveolitis, vasculitis, emphysema, pneumonia, and bronchiectasis.COPYRIGHT KIPO 2017